Penetration of cefpirome into sputum in chronic respiratory infections: comparison of administration of 0.5 g and 1.0 g in the same patient

Int J Clin Pharmacol Res. 1993;13(4):225-9.

Abstract

This study evaluated the sputum penetration of cefpirome following slow intravenous infusion of 0.5 and 1.0 g using a comparative cross-over design to reduce variability. Five patients with chronic respiratory tract infections were randomized to receive either 0.5 g followed by 1.0 g, or by 1.0 g followed by 0.5 g cefpirome, by slow intravenous infusion over 1 h, with a 24-h wash-out period between each treatment. With the exception of one patient, sputum concentration correlated well with plasma concentration. Higher sputum levels of cefpirome were achieved following the higher dose.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Cefpirome
  • Cephalosporins / administration & dosage
  • Cephalosporins / blood
  • Cephalosporins / pharmacokinetics*
  • Cephalosporins / therapeutic use
  • Chronic Disease
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Respiratory Tract Infections / drug therapy*
  • Sputum / metabolism*

Substances

  • Cephalosporins